Maven Capital Partners led the investment round with backing from Dowgate Capital to accelerate commercial growth.
"The funding secured represents a significant milestone in Real World Health's mission to equip NHS organisations with the tools they desperately need to unlock the hidden potential within their data. The tangible results we've achieved with existing clients, including reducing surgery backlog and improving mental health resource allocation, demonstrate the transformative potential of our solutions. This investment fuels our ability to deliver this impact on a wider scale, ultimately contributing to a more efficient, sustainable, and patient-centred NHS."
Toscafund Asset Management led the round, with co-investment from Maven Capital Partners.
"This investment from Maven helps us to reach our ambitious growth plans and expansion into new markets, as well as our continued drive to deliver market-leading communications solutions across the capital markets. We’re thrilled to welcome such a high calibre investor on board who believes in our vision."
Maven Capital Partners backs the Twilio consultancy as it targets growth across the American market.
"Organisations are increasingly seeking to leverage cutting-edge technologies to enhance customer experience (CX) and operational efficiencies, particularly within their contact centers. Twilio Flex’s CustomerAI technology is transformative, reducing agents’ workloads and streamlining workflows through such things as AI-driven post-work automated summaries, and real-time customer sentiment analysis."
Maven Capital Partners backed the follow-on financing round to support US expansion.
"With conversational AI and virtual assistant technologies projected to fuel a 24% growth in the contact center market in 2024 (Gartner), this is a key moment for CX innovation. These new technologies can provide massive benefits, but they must be deployed and used in the right ways. We’ve built a business on ensuring that they are,"
The Edinburgh biotech uses the capital to scale its 3D bioprinted tumour models across the UK, Europe, and the US.
"Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to accelerate oncology drug development significantly."
